News from NORD

CORD Offers Consensus Framework for Ethical Collaboration

Publish date: February 17, 2017

 

The Canadian Organization for Rare Disorders (CORD) has developed a Consensus Framework to encourage ethical collaboration among patient organizations, health care professionals, and the pharmaceutical industry.

Recommended Reading

VIDEO: Despite toxicities, ibrutinib is beneficial for treatment-resistant graft-vs.-host disease
MDedge Dermatology
New histopathologic marker may aid dermatomyositis diagnosis
MDedge Dermatology
Incidence of IBD is elevated in hidradenitis suppurativa patients
MDedge Dermatology
Hyperkeratotic Papules on the Medial Aspects of the Feet
MDedge Dermatology
IgG4-related disease can strike any organ system
MDedge Dermatology
Rituximab is dramatically effective in IgG4-related disease
MDedge Dermatology
NORD Seeks Input Regarding Patient Protections and ACA
MDedge Dermatology
Rare Disease Day 2017 Will Highlight Research Theme
MDedge Dermatology
NORD to Partner Again With Hole in the Wall Gang Camp
MDedge Dermatology
Apply Now to Join NORD’s Charity Marathon Team
MDedge Dermatology